Publication: Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section
| dc.contributor.author | Tavazzi, Guido | |
| dc.contributor.author | Rosselló, Xavier | |
| dc.contributor.author | Grand, Johannes | |
| dc.contributor.author | Gierlotka, Marek | |
| dc.contributor.author | Sionis, Alessandro | |
| dc.contributor.author | Ahrens, Ingo | |
| dc.contributor.author | Hassager, Christian | |
| dc.contributor.author | Price, Susanna | |
| dc.date.accessioned | 2024-10-04T13:22:47Z | |
| dc.date.available | 2024-10-04T13:22:47Z | |
| dc.date.issued | 2022-09-29 | |
| dc.description | This is a postprint (Accepted Manuscript) of an article published by Oxford in European Heart Journal. Acute Cardiovascular Care on 2022 September 29, available online: https://doi.org/10.1093/ehjacc/zuac087 | |
| dc.description.abstract | Aims: Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to 50% of cases. Few recommendations exist with intermediate-low level of evidence on CS management and no data on adherence across centres exist. We performed a survey to frame CS management at multinational level. Methods and results: An international cross-sectional survey was created and approved by European Society of Cardiology-Acute Cardiovascular Care Association board. A total of 337 responses from 60 countries were obtained. Data were assessed by the hospital level of care of the participants. The most common cause of CS was AMI (AMI-CS-79.9%) with significant difference according to hospital levels (P = 0.001), followed by acutely decompensated heart failure (HF) (13.4%), myocarditis (3.5%), and de novo HF (1.75%). In 37.8%, percutaneous coronary intervention (PCI) is performed to all CS-patients as a standard approach, whereas 42.1% used PCI if electrocardiogram suggestive of ischaemia and 20.1% only if Universal definition of myocardial infarction criteria are fulfilled. Management (catecholamine titration and mechanical circulatory support escalation) is driven by mean arterial pressure (87.1%), echocardiography (84.4%), and lactate levels (83.4%). Combination of vasopressor and inotrope is chosen with the same frequency (37.7%) than inotrope alone as first-line pharmacological therapy (differences amongst hospital levels; P > 0.5). Noradrenaline is first-line vasopressor (89.9%) followed by dopamine (8.5%), whereas dobutamine is confirmed as the first-line inotrope (65.9%). Conclusion: Cardiogenic shock management is heterogenous and often not adherent to current recommendations. Quality improvement on an international level with evidence-based quality indicators should be developed to standardize diagnostic and therapeutic pathways. | en |
| dc.format.number | 9 | es_ES |
| dc.format.page | 706 | es_ES |
| dc.format.volume | 11 | es_ES |
| dc.identifier.citation | Tavazzi G, Rossello X, Grand J, Gierlotka M, Sionis A, Ahrens I, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section. Eur Hear Journal Acute Cardiovasc Care. 2022 Sep 29;11(9):706-11. | en |
| dc.identifier.doi | 10.1093/ehjacc/zuac087 | |
| dc.identifier.e-issn | 2048-8734 | es_ES |
| dc.identifier.journal | European heart journal. Acute cardiovascular care | es_ES |
| dc.identifier.other | http://hdl.handle.net/20.500.13003/18600 | |
| dc.identifier.pubmedID | 35941730 | es_ES |
| dc.identifier.pui | L638690058 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/23429 | |
| dc.identifier.wos | 837522700001 | |
| dc.language.iso | eng | en |
| dc.publisher | Oxford University Press | |
| dc.relation.publisherversion | https://doi.org/10.1093/ehjacc/zuac087 | en |
| dc.rights.accessRights | open access | en |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject.decs | Norepinefrina | * |
| dc.subject.decs | Dopamina | * |
| dc.subject.decs | Resultado del Tratamiento | * |
| dc.subject.decs | Estudios Transversales | * |
| dc.subject.decs | Humanos | * |
| dc.subject.decs | Intervención Coronaria Percutánea | * |
| dc.subject.decs | Dobutamina | * |
| dc.subject.decs | Lactatos | * |
| dc.subject.decs | Choque Cardiogénico | * |
| dc.subject.mesh | Dobutamine | * |
| dc.subject.mesh | Treatment Outcome | * |
| dc.subject.mesh | Shock, Cardiogenic | * |
| dc.subject.mesh | Humans | * |
| dc.subject.mesh | Norepinephrine | * |
| dc.subject.mesh | Dopamine | * |
| dc.subject.mesh | Cross-Sectional Studies | * |
| dc.subject.mesh | Lactates | * |
| dc.subject.mesh | Percutaneous Coronary Intervention | * |
| dc.title | Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section | en |
| dc.type | research article | en |
| dc.type.hasVersion | SMUR | es_ES |
| dspace.entity.type | Publication | |
| relation.isPublisherOfPublication | 465a0b1e-d9df-4342-b738-86ffcafc4bcf | |
| relation.isPublisherOfPublication.latestForDiscovery | 465a0b1e-d9df-4342-b738-86ffcafc4bcf |


